Performance of the Acoustic Based CADScor System in Coronary Artery Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jill Fife, RN
- Phone Number: 405-951-8607
- Email: bethany.fife@integrishealth.org
Study Contact Backup
- Name: Linda Pitchford, RN, APRN
- Phone Number: 405-949-3648
- Email: linda.pitchford@integrishealth.org
Study Locations
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- Integris Baptist Medical Center
-
Contact:
- Jill Fife, RN
- Phone Number: 405-951-8607
- Email: bethany.fife@integrishealth.org
-
Contact:
- Linda Pitchford, RN, APRN
- Phone Number: 405-949-3648
- Email: linda.pitchford@integrishealth.org
-
Contact:
- Jon p Blaschke, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion:
- Signed ICF
- Male or female, aged 30 years or above
- Symptoms suggestive of stable coronary artery disease
- No history of coronary artery disease(prior myocardial infarction, percutaneous coronary intervention or coronary artery bypass graft).
Exclusion:
- Asymptomatic for angina or chest pain
- Implanted donor heart
- Previous Coronary Artery Bypass Graft(CABG)
- Previous Coronary Stenting or known CAD
- Arrhythmia causing non-sinus rhythm
- Fragile or compromised skin, or abnormal anatomy or significant operation scars in the fourth left int3er Costal 9IC4-L) recording area
- Implanted mechanical heart or mechanical heart pump
- Implanted pacemaker or Cardioverter Defibrillator(ICD), other implanted active electronics or act5ive electronic support equipment closer than 50 cm to the CADScore System.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Primary Objective
Time Frame: From enrollment through 1 year
|
To determine that the sensitivity of the CAD score in low to intermediate-risk patients referred for coronary CTA in non-inferior to the device specified sensitivity at 89%.
|
From enrollment through 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jon P Blaschke, MD, Integris Baptist Medical Center
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Integrisbmc
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.